Piper Sandler Downgrades Antares Pharma (ATRS) to Neutral

Piper Sandler analyst David Amsellem downgraded Antares Pharma (NASDAQ: ATRS) from Overweight to Neutral with a price target of $5.60 (from $6.00).

For an analyst ratings summary and ratings history on Antares Pharma click here. For more ratings news on Antares Pharma click here.

Shares of Antares Pharma closed at $5.58 yesterday.

You May Also Be Interested In

• Unicycive Therapeutics (UNCY) PT Raised to $15 at Benchmark Following Q2 Results
• Rubrik Inc (RBRK) PT Raised to $120 at Oppenheimer; Sees Another 'Beat and Raise'
• Jefferies Downgrades IDP Education (IEL:AU) (IDPUF) to Hold